New York, USA - December 9, 2024 - This joint effort with NIH, one of the US Department of Health and Human Services, was once in a lifetime chance for the company to introduce new drug solutions. At the show, the representatives of Creative Biolabs were demonstrating how advanced cancer therapeutics are achieved through use of engineered cells.
Event Highlights
The launch of CAR-T cell therapy was one of the major topics that participants were acquainted with during the course of the symposium. The expert team at Creative Biolabs was able to use T cells more efficiently by designing complex modifications to their structures and thereby expanding their application in the treatment of cancer.
* Through the Smart™ CAR platform, Creative Biolabs ensures that innovative CAR constructs are developed in order to enhance the quality of the targeted CAR therapies.
* The mRNA-based CAR cell platform is based on a transient expression technology which is low risk and suitable for short-term immune modulation.
* CRISPR-edited CAR-T cell engineering offers a useful and efficacious approach to modification which allows scientists to create an even more affordable and specific CAR-T treatment or product.
Building upon its robust cell engineering capabilities, Creative Biolabs has been able to successfully introduce its CellRapeutics™ in vivo cell engineering medical solutions and its comprehensive off-the-shelf allogeneic immune cell therapy medical solutions:
* The CellRapeutics™ platform uses potent vectorized CRISPR/Cas9 systems to facilitate the integration of vectors in vivo using delivery systems for local delivery of immune cells. This service offered includes round and individualized enhancement where vector graphic design and functional assays are embedded.
The cell therapy initiative supports the transfer of allogeneic therapies and the transfer of primary border flanked by a matrix of a project life cycle from initiation to granting the clinical trial authorization in a cost effective way, time effective with high quality.
Additionally, the organization showcased results it has achieved in the sector of single domain antibody (SdAb) cloning. An expert from Creative Biolabs elaborated, "Single-domain antibodies increase the effectiveness of targeted drug generation for complex targets, and they are most beneficial in such situations." Applications of phage display, yeast display, and single B cell sorting techniques allow Creative Biolabs to offer clients the efficient and effective single-domain antibody discovery services.
Furthermore, pre-made library screening for peptides, proteins, and cells is provided by Creative Biolabs, and thus, effective binders of various challenging targets can be rapidly isolated. These binders are important in drug discovery, vaccine development, and immunotherapy.
* The antibody library screening services cover human functional antibody discovery, bispecific antibody discovery, cell-targeting antibody discovery, and peptide/protein antibody discovery.
* The peptide library screening services include screening for particulate-binding peptides, soft material-binding peptides, cell-selective peptides, and disease-specific peptides.
Creative Biolabs demonstrated its profound knowledge and vast experience in the design and development of cancer therapies in several areas. For more information, please visit https://www.creative-biolabs.com.
Company Overview
Creative Biolabs, being an innovative leader in the field of biotechnology, assists international cancer researchers by providing efficient and effective solutions for the discovery of drug substances and targets. In the month of December, Creative Biolabs will also attend the European Macrophage and Dendritic Cell Biology and Antibody Engineering & Therapeutics (US), respectively, to forge new paths in therapeutic development with existing partners.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com
